1790-91-6 Usage
General Description
2,3-Dichloro-6,7-dimethoxyquinoxaline is a complex organic compound that falls under the category of quinoxalines. Quinoxalines are heterocyclic compounds, meaning they contain atoms of at least two different elements as part of their main ring structure. In the case of 2,3-Dichloro-6,7-dimethoxyquinoxaline, those elements are carbon, nitrogen, hydrogen, chlorine, and oxygen. Known for its versatility, it is used in various scientific capacities, particularly in the field of medicinal chemistry, due to its pharmacological potential. The attributes of halogens and methoxy groups contribute to this compound's interesting biological activity. Like other chemicals, specific safety and handling precautions are needed to mitigate health hazards.
Check Digit Verification of cas no
The CAS Registry Mumber 1790-91-6 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 1,7,9 and 0 respectively; the second part has 2 digits, 9 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 1790-91:
(6*1)+(5*7)+(4*9)+(3*0)+(2*9)+(1*1)=96
96 % 10 = 6
So 1790-91-6 is a valid CAS Registry Number.
InChI:InChI=1/C10H8Cl2N2O2/c1-15-7-3-5-6(4-8(7)16-2)14-10(12)9(11)13-5/h3-4H,1-2H3
1790-91-6Relevant articles and documents
Novel [1,2,4]Triazolo[4,3-a]Quinoxaline Derivative, Method For Preparing Same, And Pharmaceutical Composition For Preventing Or Treating BET Protein-Related Diseases, Containing Same As Active Ingredient
-
Paragraph 0976-0979, (2020/02/20)
Provided are a novel [1,2,4]triazolo[4,3-a]quinoxaline derivative, a method for preparing the same, and a pharmaceutical composition for preventing or treating bromodomain extra-terminal (BET) protein-related diseases including cancer and autoimmune disea
Imidazoquinoxaline protein tyrosine kinase inhibitors
-
, (2008/06/13)
Novel imidazoquinoxalines and salts thereof, pharmaceutical compositions containing such compounds, and methods of using such compounds in the treatment of protein tyrosine kinase-associated disorders such as immunologic disorders.
